Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: dementia is increasingly recognised as life-limiting condition. Although the benefits of acetylcholinesterase inhibitors (AChEIs) on cognition and function are well established, their effect on survival is less clear. Objective: to investigate associations between AChEI prescription and mortality in patients with Alzheimer's dementia (AD) in a naturalistic setting, using detailed baseline data on cognition, functioning, and mental and physical wellbeing. Methods: we used a large mental healthcare database in South London, linked to Hospital Episode Statistics and Office for National Statistics mortality data, to assemble a retrospective cohort. We conducted a survival analysis adjusting for a wide range of potential confounders using propensity scores to reduce the impact of confounding by indication. Results: of 2,464 patients with AD, 1,261 were prescribed AChEIs. We detected a strong association between AChEI receipt and lower mortality (hazard ratio = 0.57; 95% CI 0.51-0.64). This remained significant after controlling for a broad range of potential confounders including psychotropic co-prescription, symptom severity, functional status and hospital admissions (hazard ratio = 0.77; 95% CI 0.67-0.87). Conclusions: in a large cohort of patients with AD, AChEI prescription was associated with reduced risk of death by more than 20% in adjusted models. This has implications for individual care planning and service development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Brodaty, H., Seeher, K., & Gibson, L. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002924 · Cited by 248
Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare
Hill, J. W., Futterman, R., Duttagupta, S., Mastey, V., Lloyd, J. R., & Fillit, H. (2002) · Neurology · doi:10.1212/wnl.58.1.62 · Cited by 181
Cited by
Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-16476-w · Cited by 72
Sharma, S., Mueller, C., Stewart, R., Veronese, N., Vancampfort, D., Koyanagi, A., Lamb, S. E., Perera, G., & Stubbs, B. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.03.009 · Cited by 72
Self-citationPredictors of mortality in people with late-life depression: A retrospective cohort study
Cai, W., Mueller, C., Shetty, H., Perera, G., & Stewart, R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.021 · Cited by 41
“It has however been shown to a have useful predictive validity of adverse outcomes in other studies on this data source (Mueller et al., 2018a; Mueller et al., 2017).”
Result
Metadata
- Authors
- Mueller, C., Perera, G., Hayes, R. D., Shetty, H., & Stewart, R.
- Venue
- Age and Ageing
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-24
- Volume
- 47
- Issue
- 1
- Pages
- 88-94
- ISSN
- 0002-0729 (ISSN-L)
- 1468-2834
- OpenAlex
- W2645645336
- Cited by
- 56
- References
- 3
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. https://app.cochat.ai/papers/10.1093/ageing/afx098
- The paper
- Mueller, C., Perera, G., Hayes, R. D., Shetty, H., & Stewart, R. (2018). Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. Age and Ageing. https://doi.org/10.1093/ageing/afx098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.